Praxis Precision Medicines Inc (PRAX) Stock: A SWOT Analysis

Company’s 36-month beta value is 2.91.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for PRAX is 16.28M, and currently, short sellers hold a 2.65% ratio of that floaft. The average trading volume of PRAX on April 19, 2024 was 188.97K shares.

PRAX) stock’s latest price update

The stock price of Praxis Precision Medicines Inc (NASDAQ: PRAX) has dropped by -8.25 compared to previous close of 50.78. Despite this, the company has seen a fall of -13.43% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-12 that Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremor Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremor

PRAX’s Market Performance

PRAX’s stock has fallen by -13.43% in the past week, with a monthly drop of -13.32% and a quarterly rise of 19.74%. The volatility ratio for the week is 7.70% while the volatility levels for the last 30 days are 9.17% for Praxis Precision Medicines Inc The simple moving average for the past 20 days is -14.18% for PRAX’s stock, with a 61.95% simple moving average for the past 200 days.

Analysts’ Opinion of PRAX

Many brokerage firms have already submitted their reports for PRAX stocks, with Truist repeating the rating for PRAX by listing it as a “Buy.” The predicted price for PRAX in the upcoming period, according to Truist is $10 based on the research report published on September 19, 2023 of the previous year 2023.

Wedbush, on the other hand, stated in their research note that they expect to see PRAX reach a price target of $4. The rating they have provided for PRAX stocks is “Neutral” according to the report published on June 06th, 2022.

H.C. Wainwright gave a rating of “Buy” to PRAX, setting the target price at $48 in the report published on December 16th of the previous year.

PRAX Trading at -8.20% from the 50-Day Moving Average

After a stumble in the market that brought PRAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.68% of loss for the given period.

Volatility was left at 9.17%, however, over the last 30 days, the volatility rate increased by 7.70%, as shares sank -16.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.20% upper at present.

During the last 5 trading sessions, PRAX fell by -13.43%, which changed the moving average for the period of 200-days by +170.09% in comparison to the 20-day moving average, which settled at $53.82. In addition, Praxis Precision Medicines Inc saw 109.11% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at PRAX starting from DeSimone Jill, who purchase 14,500 shares at the price of $1.75 back on Oct 05 ’23. After this action, DeSimone Jill now owns 14,500 shares of Praxis Precision Medicines Inc, valued at $25,375 using the latest closing price.

Souza Marcio, the Chief Executive Officer of Praxis Precision Medicines Inc, purchase 10,000 shares at $1.06 during a trade that took place back on Jun 27 ’23, which means that Souza Marcio is holding 45,002 shares at $10,587 based on the most recent closing price.

Stock Fundamentals for PRAX

Current profitability levels for the company are sitting at:

  • -51.64 for the present operating margin
  • 0.57 for the gross margin

The net margin for Praxis Precision Medicines Inc stands at -50.12. The total capital return value is set at -1.75. Equity return is now at value -169.13, with -121.41 for asset returns.

Based on Praxis Precision Medicines Inc (PRAX), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -44.54. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is 1192.2.

Currently, EBITDA for the company is -125.94 million with net debt to EBITDA at 0.62. When we switch over and look at the enterprise to sales, we see a ratio of 293.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.39.

Conclusion

In a nutshell, Praxis Precision Medicines Inc (PRAX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts